TKTatiana L. Kornishina

Tatiana L. Kornishina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatiana L. Kornishina has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ventricular arrhythmias in a child with a congenital heart tumor: a case report

    by E. V. Timofeev, G. V. Kondratiev, T. L. Kornishina

    Желудочковые нарушения ритма у ребёнка с врождённой опухолью сердца (клинический случай)


  • COMPARATIVE ANALYSIS OF EARLY AND LATE ADMINISTRATION OF THE RITUXIMAB BIOSIMILAR BCD020 FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDREN. RESULTS OF A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

    by E.M. Kalashnikova, E.A. Isupova, E.V. Gaidar, V.V. Masalova, K.E. Belozerov, L.S. Sorokina, M.A. Kaneva, R.K. Raupov, E.D. Sysoeva, T.L. Kornishina, et al.

  • Open Access

    Using HScore for Evaluation of Hemophagocytosis in Multisystem Inflammatory Syndrome Associated with COVID-19 in Children

    by Ilia S. Avrusin, Natalia N. Abramova, Konstantin E. Belozerov, Liudmila V. Bregel, Olesya S. Efremova, Alla A. Vilnits, Julia E. Konstantinova, Eugenia A. Isupova, Tatiana L. Kornishina, Vera V. Masalova, et al.

    Hemophagocytic syndrome is a key point in the pathogenesis of severe forms of multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C). The factors associated with hemophagocytosis in patients with MIS-C were assessed in the present study of 94 boys and 64 girls ranging in age from 4 months to 17 years, each of whose HScore was calculated. In accordance with a previous analysis, patients with HScore ≤ 91 (n = 79) and HScore > 91 (n = 79) were compared. Patients with HScore > 91 had a higher frequency of symptoms such as cervical lymphadenopathy, dry cracked lips, bright mucous, erythema/swelling of hands and feet, peeling of fingers, edematous syndrome, hepatomegaly, splenomegaly, and hypotension/shock. They also had a higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and D-dimer levels, and a tendency to anemia, thrombocytopenia, and hypofibrinogenemia. They more often needed acetylsalicylic acid and biological treatment and were admitted to ICU in 70.9% of cases. Conclusion: The following signs of severe MIS-C were associated with HScore > 91: myocardial involvement, pericarditis, hypotension/shock, and ICU admission.


  • OUTCOMES OF TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS USING THE BIOSIMILAR RITUXIMAB BCD020 COMPARED WITH THE STANDARD NON-BIOLOGIC THERAPY. A RETROSPECTIVE COHORT STUDY

    by E.M. Kalashnikova, R.K. Raupov, V.V. Masalova, E.A. Isupova, E.V. Gaidar, M.F. Dubko, L.S. Snegireva, L.S. Sorokina, T.L. Kornishina, M.A. Kaneva, et al.

  • MANIFESTATIONS PECULIARITIES OF JUVENILE ARTHRITIS WITH SYSTEMIC ONSET IN PATIENTS WITH THE RESPIRATORY LESIONS’ DEVELOPMENT AT THE ONSET OF THE DISEASE. RESULTS OF A SINGLE-CENTER RETROSPECTIVE COHORT STUDY AND A BIBLIOGRAPHICAL REVIEW

    by K.E. Belozerov, N.M. Solomatina, N.N. Abramova, E.A. Isupova, E.V. Gaidar, M.A. Kaneva, T.L. Kornishina, V.V. Masalova, O.V. Kalashnikova, I.A. Chikova, et al.

    Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.

  • Open Access

    Determination of Risk Factors for Severe Life-Threatening Course of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children

    by Ilia S. Avrusin, Natalia N. Abramova, Konstantin E. Belozerov, Gleb V. Kondratiev, Liudmila V. Bregel, Olesya S. Efremova, Alla A. Vilnits, Julia E. Konstantinova, Eugenia A. Isupova, Tatiana L. Kornishina, et al.

    Multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a life-threatening condition that often requires intensive care unit (ICU) admission. The aim of this study was to determine risk factors for severe/life-threatening course of MIS-C. The study included 166 patients (99 boys, 67 girls) aged 4 months–17 years (median 8.2 years). The criterion of severity was the fact of ICU admission. To conduct a comparative analysis, MIS-C patients were divided into two groups: patients hospitalized in the ICU (n = 84, 50.6%) and those who did not need ICU admission (n = 82, 49.4%). Patients with a more severe course of MIS-C were significantly older. They had a higher frequency of signs such as rash, swelling, hepatomegaly, splenomegaly, and neurological and respiratory symptoms. Hypotension/shock and myocardial involvement were much more common in patients with severe MIS-C. These patients had a more significant increase in CRP, creatinine, troponin, and D-dimer levels. Additionally, the presence of macrophage activation syndrome was higher in patients admitted to the ICU. Conclusion: Nineteen predictors of severe course of MIS-C were found, out of which hepatomegaly, splenomegaly, D-dimer > 2568 ng/mL, troponin > 10 pg/mL were mainly associated with the probability of being classified as early predictors of severe MIS-C requiring ICU admission.


  • Open Access

    Anthracycline-induced cardiotoxicity in a child with acute lymphoblastic leukaemia against the background of new coronavirus infection

    by G. V. Kondratiev, М. Е. Мельников, S. A. Kulyova, A. S. Chepelev, S. L. Bannova, T. L. Kornishina, I. A. Reshetnyak, K. D. Murasheva

    Anthracycline chemotherapy drugs are widely used for the treatment of various tumors but they are associated with high cardiotoxicity. The novel coronavirus disease can also negatively affect the heart function. In this article, we report a case of anthracycline-related cardiotoxicity in a child with refractory acute lymphoblastic leukemia and the novel coronavirus disease, describing changes in instrumental and laboratory parameters observed over time during the treatment and providing a description of autopsy samples of the myocardium. The patient’s parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.


  • Open Access

    Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study

    by Mikhail Kostik, Elvira Kalashnikova, Raupov Rinat, Eugenia Isupova, Ekaterina Gaidar, Anton A. Soloviev, Vera Masalova, Ludmila Snegireva, Tatyana Kornishina, Natalia Abramova, et al.

    Background: Pediatric lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) in children, determining the outcomes of the disease. There are no standardized treatment protocols for pediatric LN, and the role of biologics has not yet been conclusively defined. Objectives: analyze the safety and efficacy of rituximab biosimilar BCD020 in pediatric patients with lupus nephritis. Methods: in a retrospective cohort study, the data from the case histories of 25 patients with LN (10 boys and 15 girls) with an onset age of 13 (9–16) years, who failed conventional non-biologic treatment or developed corticosteroid dependence/toxicity, were included. The diagnosis was made using Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. Rituximab biosimilar BCD020 was prescribed in a dosage of 375 mg/m2 every week (2–4 infusions) with repeated courses every 6–12 months (2–4 infusions) according to disease activity, B-cell depletion, and IgG levels. The dynamics of clinical and laboratory data, the activity of the disease by SLEDAI, and corticosteroid doses were assessed at the onset and during the rituximab trial. Results: The main patient’s characteristics were: Pre-rituximab non-biologic conventional treatment included: cyclophosphamide 15 (60%), MMF 8 (32%), azathioprine 3 (12%), hydroxychloroquine 12 (48%), and pulse therapy of methylprednisolone followed by oral methylprednisolone 25 (100%). The time before rituximab was 7.0 (3.0–24.0) months, and the whole observation period was 7.0 (0; 24) months. The initial pre-rituximab treatment slightly reduced SLEDAI levels and the proportion of patients with LN. A significant reduction of SLEDAI, the anti-dsDNA level, proteinuria, hematuria, C4 complement, ESR, and the median corticosteroid dose by 80% from the initial value, as well as the proportion of patients without corticosteroids, was observed after rituximab administration. Two deaths were observed due to catastrophic SLE with macrophage activation syndrome, accompanied by a severe infection (invasive aspergillosis, n = 2). Three patients developed serious adverse events: pneumonia (n = 2), transient agranulocytosis (n = 1) after the third rituximab infusion, and meningitis, caused by Listeria monocytosis, after the first rituximab infusion. Eight patients received antibacterial treatment for different respiratory infections without hospital admissions. Conclusions: Rituximab biosimilar BCD020 showed effectiveness in LN, whereas previous non-biologic treatment was insufficiently effective. Randomized controlled trials are required to evaluate the efficacy and safety of rituximab and evaluate the benefits when compared with conventional SLE treatment.


  • Open Access

    The predictors of severe course of multisystem inflammatory syndrome associated with the new coronavirus infection COVID-19 in children: results of a retrospective-prospective multicenter study

    by Ilia S. Avrusin, Н. Н. Абрамова, Konstantin E. Belozerov, Olesya S. Efremova, L.V. Bregel, Gleb V. Kondratiev, E. А. Dondurey, Alla A. Vilnitz, Yu. E. Konstantinovа, Т.е. Бурцева, et al.

    BACKGROUND:Multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a rare but severe disease in which various organs and systems are affected, including heart, lungs, kidneys, brain, skin, eyes and organs of the gastrointestinal tract. MIS-C is rather difficult to diagnose, since it has much in common with the infectious process, and Kawasaki disease. However, MIS-C course is more severe and therefore patients need hospitalization in the intensive care unit in half of the cases. AIM:To determine the factors associated with severe course of MIS-C, requiring hospitalization of patients in the intensive care unit. MATERIALS AND METHODS:The retrospective study included 166 patients (99 boys, 67 girls), aged 4 months to 17 years (median 8.2 years), with a diagnosis of multisystem inflammatory syndrome associated with COVID-19 in children. To conduct a comparative analysis, patients with MIS-C were divided into two groups: group 1 patients hospitalized in the intensive care unit (n= 84, 50.6%), and group 2 patients who did not need hospitalization in the intensive care unit (n= 82, 49.4%). RESULTS:Patients with a more severe course of MIS-C were significantly older. They had a higher frequency of signs such as rash, swelling, hepatomegaly, splenomegaly, neurological and respiratory symptoms. Hypotension/shock and myocardial involvement were much more common in patients with severe MIS-C. These patients had a more significant increase in CRP, creatinine, troponin and D-dimer levels. Also, in patients hospitalized in the intensive care unit, signs of hemophagocytic syndrome were more often observed. CONCLUSIONS:The main factors determining the severity of MIS-C are damage to the cardiovascular system, the central nervous system, the presence of respiratory and hemodynamic disorders, especially hemophagocytosis.


  • Open Access

    COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report

    by Konstantin E. Belozerov, Ilia S. Avrusin, Lyubov I. Andaryanova, Anna M. Guseva, Zaira S. Shogenova, Irina N. Belanovich, Anna V. Lobacheva, Tatiana L. Kornishina, Eugenia A. Isupova, Vera V. Masalova, et al.

    Background: Several cases of skin and central nervous system vasculopathy associated with COVID-19 in children have been published, but the information is rather limited. Our study aimed to describe these cases of vasculitis associated with COVID-19 in children. Methods: In the retrospective-prospective case series study we included information regarding four children with COVID-19-associated vasculitis. In every case, we had a morphological description and the etiology was confirmed via real-time polymerase chain reaction during a tissue biopsy. Results: The most involved systems were skin (4/4), respiratory (3/4), cardiovascular (2/4), nervous (1/4), eye (1/4), kidney (1/4), and inner year (1/4). All patients had increased inflammatory markers and thrombotic parameters (D-dimer). No patient met the criteria for multisystem inflammatory syndrome in children. Two patients met polyarteritis nodosa criteria, one met Henoch–Schonlein purpura criteria, and one met unclassified vasculitis criteria. All patients were treated with systemic glucocorticosteroids (two-pulse therapy). Non-biologic DMARDs were prescribed in all cases; 1/4 patients (25%) was treated with intravenous immunoglobuline, and 3/4 (75%) were treated with biologics (etanercept, tocilizumab, and adalimumab). Conclusions: Vasculitis associated with COVID-19 could be a life-threatening condition; SARS-CoV-2 might be a new trigger or etiological agent for vasculitis and other immune-mediated diseases. Further research and collection of similar cases are required.